UPDATE: Brean Capital Reiterates on Celgene Corporation Following Strong 3Q13 Results, Raised FY13 Guidance

In a report published Friday, Brean Capital analyst Gene Mack reiterated a Buy rating on Celgene Corporation (NASDAQ: CELG ), and raised the price target from $153.00 to $191.00. In the report, Brean Capital noted, “CELG reported 3Q13 of $1.56 per share, beating our $1.50 estimate and inline with consensus